IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas

Amit Akirov*, Yona Greenman, Benjamin Glaser, Irena S’chigol, Yossi Mansiterski, Yoav Eizenberg, Ilana Shraga-Slutzky, Ilan Shimon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Hyperprolactinemia is common in acromegaly and in these patients, insulin-like growth factor (IGF)-1 level may decrease with dopamine agonist. We report a series of patients with prolactinoma and a paradoxical increase of IGF-1 levels during cabergoline treatment. Methods: Clinical characteristics and response to treatment of patients with prolactinomas, in whom normal or slightly elevated baseline IGF-1 levels increased with cabergoline. Results: The cohort consisted of ten prolactinoma patients (nine males, mean age 48 ± 14 years). Mean adenoma size was 23.8 ± 16.2 mm, with cavernous sinus invasion in eight. In five patients baseline IGF-1 levels were normal and in four levels were 1.2–1.5-fold the upper limit of the normal (ULN). One patient had IGF-1 measured shortly after initiating cabergoline and it was 1.4 × ULN. During cabergoline treatment (dose range 0.5–2 mg/week) PRL normalization was achieved in all and tumor shrinkage occurred in seven patients. The mean IGF-1 increase on cabergoline was 1.7 ± 0.4 × ULN. Cabergoline dose reduction or interruption was attempted in five patients and resulted in decreased IGF-1 levels in all, including normalization in two patients. Three patients were eventually diagnosed with acromegaly, one was referred for pituitary surgery followed by complete remission, another patient was switched to somatostatin analogue, and the third was treated by combination of somatostatin analogues with pegvisomant, with reduction of IGF-1 in all these patients. Conclusion: IGF-1 levels may increase to clinically significant levels during cabergoline treatment for PRL-adenoma. We suggest IGF-1 monitoring in all patients treated with dopamine agonists and not only in those presenting symptoms of acromegaly.

Original languageEnglish
Pages (from-to)406-413
Number of pages8
JournalPituitary
Volume21
Issue number4
DOIs
StatePublished - 1 Aug 2018

Funding

FundersFunder number
Medison
Pfizer
Novartis

    Keywords

    • Acromegaly
    • Dopamine agonist
    • IGF-1
    • Prolactinoma

    Fingerprint

    Dive into the research topics of 'IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas'. Together they form a unique fingerprint.

    Cite this